Checklist:
- Observational study of prescription weight-loss drugs and mental health
- Higher rates of depression, counseling, suicidal thoughts, and attempts
- Stronger associations when weight was regained or increased
- Experts stress correlation is not the same as causation
- Possible role of older obesity medications and mood-related side effects
- Doctors urged to screen and monitor for mental health changes
This story discusses suicide. If you or someone you know is having thoughts of suicide, please contact the Suicide & Crisis Lifeline at 988 or 1-800-273-TALK (8255).
Adults who said they used prescription weight-loss drugs in the past year showed higher levels of depression, mental-health counseling, suicidal thoughts, and suicide-related behaviors than people who did not use them, according to an observational study from South Korea. The findings caught attention because the differences were not small, especially among people who had gained weight again after trying the medication.
The study looked at 27,741 adults, including 846 who had taken a prescription weight-control drug during the previous year. Researchers compared that group with 26,895 participants who had not used these medications, then examined self-reported mental health outcomes across the sample. The results linked weight-loss drug use with a 1.9 times higher likelihood of depression, twice the odds of mental-health counseling, 2.7 times the odds of suicidal thoughts, and 1.7 times the odds of a suicide attempt.
One of the sharpest signals came from the subgroup that regained weight. In that group, the connection between weight-loss medication use and suicidal ideation was even stronger, suggesting that the emotional fallout of failed or reversed weight loss may matter just as much as the drugs themselves. The researchers said the pattern may reflect a mix of biological effects and the psychological pressure that can come with stalled progress.
The study was published in the Korean Journal of Family Practice and used data collected between 2013 and 2022. That detail matters, because much of that period came before modern GLP-1 and GLP-1/GIP drugs became widely used in South Korea, meaning the sample likely included older anti-obesity medications such as phentermine, diethylpropion, phendimetrazine, topiramate, and orlistat.
That timeline has real weight. Older stimulant-type medications have long been associated with anxiety, insomnia, and mood changes, so the findings may not map neatly onto the newer drugs that dominate today’s weight-loss conversation. Even so, the study adds another layer of caution around a category of medicine already under intense public scrutiny.
Bonnie Mitchell, a licensed professional clinical counselor in California, pointed out that the research was observational and cross-sectional, which means it can show a link but not prove that the medication caused the mental health symptoms. That distinction is huge. People who seek weight-loss treatment may already be dealing with depression, anxiety, body image stress, or the emotional strain of living with severe obesity.
Mitchell also noted that severe obesity itself is often tied to higher baseline rates of depression, anxiety, and body dysmorphia. When weight does not come off, or comes back, the emotional hit can be brutal, bringing guilt, shame, and helplessness along with it. In that kind of environment, it becomes hard to separate a medication effect from the deeper psychological pressure surrounding weight control.
Still, the warning signs should not be brushed off. The counselor said that any active suicidal thoughts call for immediate emergency medical care, and new or worsening depression during treatment should trigger a fast conversation with a clinician. Patients and families should watch for persistent low mood, anxiety, sleep problems, agitation, loss of interest in normal activities, or personality changes that suddenly show up.
Mitchell recommended that doctors take a baseline mental health history before starting a patient on a new weight-loss drug. That includes asking about past depression, bipolar disorder, suicidal thoughts, or prior attempts, then checking back regularly during dose changes to see how the person is doing emotionally as well as physically.
Drug makers also acknowledge the issue in different ways. Eli Lilly, which makes tirzepatide under the brand name Zepbound, includes depression and thoughts of suicide in its safety information and tells patients to pay close attention to changes in mood, behavior, feelings, or thoughts. Novo Nordisk says its Wegovy trials found less than 1% of participants experienced suicidal ideation or behavior and reports no difference between semaglutide 2.4 mg and placebo.
For now, the conversation around weight-loss drugs is getting sharper, not quieter. The promise of fast, dramatic weight loss still draws huge interest, but the mental health angle is now impossible to ignore, especially when weight regain enters the picture and the emotional stakes climb fast.
